zinc finger and SCAN domain containing 32Genealiases: HCCS-5 · ZNF434
Q-omics provides the consensus-scored ZSCAN32 profile across patient tissues and cancer cell-line models. ZSCAN32 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZSCAN32 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZSCAN32 RNA expression shows 21,135 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, and UVM as cancer lineages where ZSCAN32 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZSCAN32 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZSCAN32 survival associations across molecular data types. ZSCAN32 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZSCAN32 RNA expression–survival associations across cancer types. High ZSCAN32 expression shows unfavorable associations in MESO, but favorable associations in HNSC, KIRC, LUAD, COAD and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZSCAN32 RNA expression.
This table summarizes ZSCAN32 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZSCAN32. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZSCAN32 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, BRCA, CHOL and STAD. The HNSC box plot shows higher ZSCAN32 RNA expression in tumor versus normal tissue (log2 FC = +0.587, t-test p < 0.001).
This table shows molecular features associated with ZSCAN32 in patient tissues and cancer cell lines. In patient samples, ZSCAN32 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZSCAN32 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
